Pancreatic cancer cells retain the epithelial-related phenotype and modify mitotic spindle microtubules after the administration of ukrain in vitro

Anti-Cancer Drugs

Volumn 23, Issue 9, 2012, Pages 935-946

  Gagliano, Nicoletta ^a   Volpari, Tatiana ^a   Clerici, Marco ^a   Pettinari, Letizia ^a   Barajon, Isabella ^a   Portinaro, Nicola ^b   Colombo, Graziano ^a   Milzani, Aldo ^a   Dalle Donne, Isabella ^a   Martinelli, Carla ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

apoptosis; epithelial to mesenchymal transition; mitotic spindle; pancreatic ductal adenocarcinoma; ukrain

Indexed keywords

ACTIN; BETA CATENIN; CASPASE 8; CYTOCHROME C; TUBULIN; UKRAIN; UVOMORULIN; VIMENTIN;

ANTIBODY LABELING; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL PROLIFERATION; CELL STRUCTURE; CELL VIABILITY; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG MECHANISM; EPITHELIAL MESENCHYMAL TRANSITION; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; MICROTUBULE; MITOSIS; PANCREAS ADENOCARCINOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SPINDLE CELL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BERBERINE ALKALOIDS; BETA CATENIN; CADHERINS; CARCINOMA, PANCREATIC DUCTAL; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; MICROSCOPY, FLUORESCENCE; MICROSCOPY, PHASE-CONTRAST; MICROTUBULES; MITOSIS; MITOTIC INDEX; MITOTIC SPINDLE APPARATUS; PANCREATIC NEOPLASMS; PHENANTHRIDINES; PHENOTYPE; TIME FACTORS;

EID: 84865960822     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32835507bc     Document Type: Article

References (57)

1. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet 2011; 378:607-620.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics. 2009. CA Cancer J Clin 2009; 59:225-249.
3. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004; 363:1049-1057.
4. Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, et al. Resected adenocarcinoma of the pancreas-616 patients: Results, outcomes, and prognostic indicators. J Gastrointest Surg 2000; 4:567-579.
5. Liu Y, Brand RE, Turzhitsky V, Kim YL, Roy HK, Hasabou N, et al. Optical markers in duodenal mucosa predict the presence of pancreatic cancer. Clin Cancer Res 2007; 13:4392-4399.
6. Ghaneh P, Costello E, Neoptolemos JP. Biology and management of pancreatic cancer. Gut 2007; 56:1134-1152.
7. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002; 2:442-454.
8. Cano CE, Motoo Y, Iovanna JL. Epithelial-to-mesenchymal transition in pancreatic adenocarcinoma. Scientific World J 2010; 10:1947-1957.
9. Kang Y, Massagué J. Epithelial-mesenchymal transitions: Twist in development and metastasis. Cell 2004; 118:277-279.
10. Semb H, Christofori G. The tumor-suppressor function of E-cadherin. Am J Hum Genet 1998; 63:1588-1593.
11. Hirohashi S. Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am J Pathol 1998; 153:333-339.
12. El-Bahrawy MA, Pignatelli M. E-cadherin and catenins: Molecules with versatile roles in normal and neoplastic epithelial cell biology. Microsc Res Tech 1998; 43:224-232.
13. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as firstline therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997; 15:2403-2413.
14. Mö ssner J. What's new in therapy of pancreatic cancer? Dig Dis 2010; 28:679-683.
15. Kretmair H. Hypericum perforatum, St John's wort. Pharmazie 1950; 5: 85-88.
16. Susak YM, Zemskov VS, Yaremchuk OY, Kravchenco OB, Yatsyk IM, Korsh OB. Comparison of chemotherapy and X-ray therapy with Ukrain monotherapy for colorectal cancer. Drugs Exp Clin Res 1996; 22:115-122.
17. Uglianitsa KN, Nefyodov LI, BrzoskoW. Evaluation of the efficacy of ukrain in the treatment of breast cancer: Clinical and laboratory studies. Drugs Exp Clin Res 1998; 24:231-239.
18. Uglianitsa KN, Nechiporenko NA, Nefyodov LI, Brzosko WJ. Ukrain therapy of stage T1N0M0 bladder cancer patients. Drugs Exp Clin Res 1998; 24:227-230.
19. Zemskov O, Prokopchuk Y, Susak S, Zemskov O, Tkachenko Y, Hodysh W, et al. Efficacy of ukrain in the treatment of pancreatic cancer. Langenbecks Arch 2002; 387:84-89.
20. Ernst E, Schmidt K. Ukrain - a new cancer cure? A systematic review of randomised clinical trials. BMC Cancer 2005; 5:69.
21. Gansauge F, Ramadani M, Pressmar J, Gansauge S, Muehling B, Stecker K, et al. NSC-631570 (ukrain) in the palliative treatment of pancreatic cancer. Results of a phase II trial. Langenbecks Arch Surg 2002; 386:570-574.
22. Gansauge F, Ramadani M, Schwarz M, Beger HG, Lotspeich E, Poch B. The clinical efficacy of adjuvant systemic chemotherapy with gemcitabine and NSC-631570 in advanced pancreatic cancer. Hepatogastroenterology 2007; 54:917-920.
23. Funel N, Costa F, Pettinari L, Taddeo A, Sala A, Chiriva-Internati M, et al. Ukrain affects pancreas cancer cell phenotype in vitro by targeting MMP-9 and intra-/extracellular SPARC expression. Pancreatology 2010; 10: 545-552.
24. Gagliano N, Pettinari L, Aureli M, Colombo E, Costa F, Carminati R, et al. Malignant phenotype of renal cell carcinoma cells is switched by ukrain administration in vitro. Anticancer Drugs 2011; 22:749-762.
25. Liepins A, Nowicky JW, Bustamante JO, Lam E. Induction of bimodal programmed cell death in malignant cells by the derivative ukrain NSC- 631570. Drugs Exp Clin Res 1996; 22:73-79.
26. Roublevskaia IN, Polevoda BV, Ludlow JW, Haake AR. Induced G2/M arrest and apoptosis in human epidermoid carcinoma cell lines by semisynthetic drug ukrain. Anticancer Res 2000; 20:3163-3167.
27. Gagliano N, Moscheni C, Torri C, Donetti E, Magnani I, Costa F, et al. Ukrain modulates glial fibrillary acidic protein, but not connexin 43 expression, and induces apoptosis in human cultured glioblastoma cells. Anti-cancer Drugs 2007; 18:669-676.
28. Nowicky JW, Hiesmayr W, Nowicky W, Liepins A. Influence of ukrain on DNA, RNA and protein synthesis in malignant cells. Drugs Exp Clin Res 1996; 22:81-91.
29. Saxton WM, Stemple DL, Leslie RJ, Salmon ED, Zavortink M, McIntosh Jr. Tubulin dynamics in cultured mammalian cells. J Cell Biol 1984; 99: 2175-2186.
30. Yvon AMC, Wadsworth P, Jordan MA. Taxol suppresses dynamics of individual microtubules in living human tumor cells. Mol Biol Cell 1999; 10:947-959.
31. Elhajouji A, Cunha M, Kirsch-Volders M. Spindle poisons can induce polyploidy by mitotic slippage and micronucleate mononucleates in the cytokinesis-block assay. Mutagenesis 1998; 13:193-198.
32. Meek DW. The role of p53 in the response to mitotic spindle damage. Pathol Biol 2000; 48:246-25
33. Scholz C, Wieder T, Starck L, Essmann F, Schulze-Osthoff K, Dorken B, et al. Arsenic trioxide triggers a regulated form of caspase-independent necrotic cell death via the mitochondrial death pathway. Oncogene 2005; 24:1904-1913.
34. Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial-mesenchymal transition: New insights in signaling, development, and disease. J Cell Biol 2006; 172:973-981.
35. Nelson WJ, Nusse R. Convergence of Wnt, b-catenin, and cadherin pathways. Science 2004; 303:1483-1487.
36. Marambaud P, Shioi J, Serban G, Georgakopoulos A, Sarner S, Nagy V, et al. A presenilin-1/g-secretase cleavage releases the E-cadherin intracellular domain and regulates disassembly of adherens junctions. EMBO J 2002; 21:1948-1956.
37. Van Es JH, Barker N, Clevers H. You WNTsome, you lose some: Oncogenes in the WNT signaling pathway. Curr Opin Genet Dev 2003; 13:28-33.
38. Nakajiama S, Doi R, Toyoda E, Tsuji S,Wada M, Koizumi M, et al. N-cadherin expression and epithelial-mesenchymal transition in pancreatic carcinoma. Clin Cancer Res 2004; 10:4125-4133.
39. Joo YE, Rew JS, Park CS, Kim SJ. Expression of E-cadherin, alpha and b-catenins in patients with pancreatic adenocarcinoma. Pancreatology 2002; 2:129-137.
40. Pawlak G, Helfman DM. Cytoskeletal changes in cell transformation and tumorigenesis. Curr Opin Genet Dev 2001; 11:41-47.
41. Savagner P. Leaving the neighborhood: Molecular mechanisms involved during epithelial-mesenchymal transition. Bioessays 2001; 23:912-923.
42. Ayollo DV, Zhitnyak IY,Vasiliev JM, Gloushankova NA. Rearrangements of the actin cytoskeleton and E-cadherin-based adherens junctions caused by neoplasic transformation change cell-cell interactions. PLoS One 2009; 4:e8027.
43. Giovannetti E, Funel N, Peters GJ, Del Chiaro M, Erozenci LA, Vasile E, et al. MicroRNA-21 in pancreatic cancer: Correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res 2010; 70:4528-4538.
44. Hwang JH, Voortman J, Giovannetti E, Steinberg SM, Leon LG, Kim YT, et al. Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS One 2010; 5:e10630.
45. Cates JM, Byrd RH, Fohn LE, Tatsas AD, Washington MK, Black CC. Epithelial-mesenchymal transition markers in pancreatic ductal adenocarcinoma. Pancreas 2009; 38:e1-e6.
46. Funel N, Giovannetti E, Del Chiaro M, Mey V, Pollina LE, Nannizzi S, et al. Laser microdissection and primary cell cultures improve pharmacogenetic analysis in pancreatic adenocarcinoma. Lab Invest 2008; 88:773-784.
47. Christiansen JJ, Rajasekaran AK. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res 2006; 66:8319-8326.
48. Christiansen JJ, Rajasekaran SA, Inge L, Cheng L, Anilkumar G, Bander NH, et al. N-glycosylation and microtubule integrity are involved in apical targeting of prostate-specific membrane antigen: Implications for immunotherapy. Mol Cancer Ther 2005; 4:704-714.
49. Ng WK. Fine-needle aspiration cytology findings of an uncommon micropapillary variant of pure mucinous carcinoma of the breast: Review of patients over an 8-year period. Cancer 2002; 96:280-288.
50. Tan DS, Potts HW, Leong AC, Gillett CE, Skilton D, Harris WH, et al. The biological and prognostic significance of cell polarity and E-cadherin in grade I infiltrating ductal carcinoma of the breast. J Pathol 1999; 189: 20-27.
51. Kartenbeck J, Haselmann U, Gassler N. Synthesis of junctional proteins in metastasizing colon cancer cells. Eur J Cell Biol 2005; 84:417-430.
52. Wicki A, Lehembre F, Wick N, Hantusch B, Kerjaschki D, Christofori G. Tumor invasion in the absence of epithelial-mesenchymal transition: Podoplanin-mediated remodeling of the actin cytoskeleton. Cancer Cell 2006; 9:261-272.
53. Pryczynicz A, Guzinska-Ustymowicz K, Dymicka-Piekarska V, Czyzewska J, Kemona A. Expression of matrix metalloproteinase 9 in pancreatic ductal carcinoma is associated with tumor metastasis formation. Folia Histochem Cytobiol 2007; 45:37-40.
54. Li YJ, Ji XR. Relationship between expression of E-cadherin-catenin complex and clinicopathologic characteristics of pancreatic cancer. World J Gastroenterol 2003; 9:368-372.
55. Pignatelli M, Ansari TW, Gunter P, Liu D, Hirano S, Takeichi M, et al. Loss of membranous E-cadherin expression in pancreatic cancer: Correlation with lymph node metastasis, high grade, and advanced stage. J Pathol 1994; 174:243-248.
56. Yilmaz M, Christofori G. Mechanisms of motility in metastasizing cells. Mol Cancer Res 2010; 8:629-642.
57. Yilmaz M, Christofori G, Lehembre F. Distinct mechanisms of tumor invasion and metastasis. Trends Mol Med 2007; 13:535-541.